Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision medicine in non-small cell lung cancer: Current applications and future directions.

Seminars in cancer biology - 1 Sept 2022

Yang Soo-Ryum, Schultheis Anne M, Yu Helena, Mandelker Diana, Ladanyi Marc, Büttner Reinhard

Abstract excerpt

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there are highly effective targeted therapies against EGFR, ALK, ROS1, BRAF, TRK, RET, and MET. In addition, investigational therapies for KRAS, NRG1, and HER2 have shown promising results and may become standard-of-care in the near future. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Precision Medicine

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 32730814
DOI: 10.1016/j.semcancer.2020.07.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision medicine in non-small cell lung cancer: Current applications and future directions.PMID 32730814Read ↗

The evolving paradigm of precision medicine in lung cancer.Semantic proximity Read ↗

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Semantic proximity Read ↗

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.Semantic proximity Read ↗

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.Semantic proximity Read ↗

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments.Semantic proximity Read ↗

Prognostic and predictive biomarkers in non-small cell lung carcinoma.Semantic proximity Read ↗

Paradigm shift in the management of metastatic Non-small Cell Lung CancerSemantic proximity Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.Semantic proximity Read ↗

Paradigm shift in the management of metastatic nonsmall cell lung cancer.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.